scholarly journals Factors that influence treatment delay in patients with colorectal cancer

Oncotarget ◽  
2016 ◽  
Vol 8 (22) ◽  
pp. 36728-36742 ◽  
Author(s):  
Irene Zarcos-Pedrinaci ◽  
Alberto Fernández-López ◽  
Teresa Téllez ◽  
Francisco Rivas-Ruiz ◽  
Antonio Rueda A ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Treatment Delay

UGT1A1*28 polymorphism in advanced colorectal cancer: The story is not yet ended.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 516-516
Author(s):  
Ahmed El Saied El Bastawisy ◽  
Amany El-Zeiny ◽  
Samar Farid ◽  
Abeer Bahnasy
Keyword(s):  
Colorectal Cancer ◽  
Advanced Colorectal Cancer ◽  
Progression Free Survival ◽  
Treatment Delay ◽  
Free Survival ◽  
Primary Endpoints ◽  
Secondary Endpoints ◽  
Group 2 ◽  
Group 1

516 Background: UGT1A1*28 polymorphism is associated with neutropenia and diarrhea in previous reports, this study tried to investigate correlation with other toxicities like vomiting. Methods: This is a prospective case control study including all eligible cases of advanced colorectal cancer. The genotypes of UGT1A1*28 was assessed in the peripheral blood and/or in tissues by PCR. Patients were divided into two groups, group 1—patients with no mutation, group 2—patients with homo or hetero mutation. All patients received standard IFL regimen. Primary endpoints were (1) comparison between the 2 groups as regard vomiting (2) assessement of the incidence of UGT1A1*28 polymorphism. Secondary endpoints were comparison between the 2 groups as regard: neutropenia, diarrhea, treatment delay, progressive diseases (PD), progression free survival (PFS), and overall survival (OS). Results: 46 cases of advanced colorectal cancer presenting to National Cancer Institute, Cairo University, aged between 19 and 71 years with a median age of 45 years were included and followed up during the period from September 2010 to January 2013 with a median follow up of 9 months. UGT1A1*28 polymorphism was present in 20 patients (43%) of them 15% are homozygous. Grade (2-4) vomiting was found in 8.3 % of group 1 versus 52.5 % of group 2. (p = 0.01). Grade (2-4) neutropenia were found in 20.8 % of group 1 versus 64.7 % of group2. (p = 0.03). Grade (2-4) diarrhea was found in 37.5 % of patients of group 1 and 27.5% of patients with group 2. (p = 0.75). Treatment delay occurred in 29.16 % of group 1 versus 72.4 % of group 2. (p = 0.02). 25% of group 1 showed PD versus 25 % of group 2. (p = 0.8). 1 year PFS was 19% in group 1 versus 23 % in group 2. (p = 0.8) while there was a trend towards better OS in group 1 (47 % versus % 35). (p = 0.07). Conclusions: UGT1A1*28 polymorphism is present frequently (43%) in a Caucasian population and is associated with more vomiting, neutropenia and treatment delay.

scholarly journals Diagnostic and treatment delay, quality of life and satisfaction with care in colorectal cancer patients: a study protocol

2013 ◽  
Vol 11 (1) ◽  
pp. 117 ◽  
Author(s):  
Salvador Pita-Fernández ◽  
Sonia Pértega-Díaz ◽  
Beatriz López-Calviño ◽  
Teresa Seoane-Pillado ◽  
Esther Gago-García ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Cancer Patients ◽  
Study Protocol ◽  
Treatment Delay ◽  
Satisfaction With Care ◽  
Colorectal Cancer Patients

scholarly journals Disparities in Colorectal Cancer Treatment Delay Within Appalachia-The Role of For-Profit Hospitals

2015 ◽  
Vol 31 (4) ◽  
pp. 382-391 ◽  
Author(s):  
Eric E. Seiber ◽  
Fabian Camacho ◽  
Muhammad Fazal Zeeshan ◽  
Teresa T. Kern ◽  
Steven T. Fleming
Keyword(s):  
Colorectal Cancer ◽  
Cancer Treatment ◽  
Treatment Delay ◽  
For Profit ◽  
Colorectal Cancer Treatment

Deletion mapping on chromosome 6 in colorectal cancer associated with ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Deletion Mapping ◽  
Chromosome 6

Predicting adherence to colorectal cancer surveillance after plypectomy

2001 ◽  
Vol 120 (5) ◽  
pp. A602-A602
Author(s):  
S RAWL ◽  
S BLACKBURN ◽  
L HACKWARD ◽  
N FINEBERG ◽  
T IMPERIALE ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Surveillance ◽  
Colorectal Cancer Surveillance

Urokinase type plasminogen activator and inhibitor type-1 plasma levels in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A600 ◽  
Author(s):  
L HERSZENYI ◽  
F FARINATI ◽  
G ISTVAN ◽  
M PAOLI ◽  
G ROVERONI ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Plasminogen Activator ◽  
Plasma Levels ◽  
Type Plasminogen Activator ◽  
Urokinase Type Plasminogen Activator ◽  
Inhibitor Type

A panel of mono- and dinucleotide microsatellite markers is required for reliable determination of the MSI status in colorectal cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A599-A599
Author(s):  
C ARNOLD ◽  
A GOEL ◽  
J CARETHERS ◽  
L WASSERMAN ◽  
C COMPTON ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Markers ◽  
Reliable Determination
Sign in / Sign up

Export Citation Format

Share Document